Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

1343550

USP

Iodixanol Related Compound D

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

Iopentol, 5-[Acetyl(2-hydroxy-3-methylpropyl)amino]-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C20H28I3N3O9
Numéro CAS:
89797-00-2
Poids moléculaire :
835.16
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

iodixanol

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

InChI

1S/C20H28I3N3O9/c1-9(29)26(5-12(32)8-35-2)18-16(22)13(19(33)24-3-10(30)6-27)15(21)14(17(18)23)20(34)25-4-11(31)7-28/h10-12,27-28,30-32H,3-8H2,1-2H3,(H,24,33)(H,25,34)

Clé InChI

IUNJANQVIJDFTQ-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Iodixanol Related Compound D USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:
  • Iodixanol Injection
  • Iodixanol

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Y0001294

Iodixanol, European Pharmacopoeia (EP) Reference Standard

Y0001292

Iodixanol impurity C, European Pharmacopoeia (EP) Reference Standard

Y0001291

Iodixanol impurity E, European Pharmacopoeia (EP) Reference Standard

Y0001293

Iodixanol impurity H, European Pharmacopoeia (EP) Reference Standard

1343517

Iodixanol, United States Pharmacopeia (USP) Reference Standard

1343540

Iodixanol Related Compound C, United States Pharmacopeia (USP) Reference Standard

1343561

Iodixanol Related Compound E, United States Pharmacopeia (USP) Reference Standard

PHR3015

Iodixanol, pharmaceutical secondary standard, certified reference material

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Nikolaos L Kelekis et al.
Clinical imaging, 28(2), 124-127 (2004-03-31)
Confluent hepatic fibrosis (CHF) is usually a feature of advanced cirrhosis, while occurrence in early stage compensated cirrhosis is uncommon. We report the imaging findings of masslike CHF in a patient with previously unsuspected compensated alcoholic cirrhosis. The combination of
Markus Selzner et al.
Annals of surgery, 240(6), 1027-1034 (2004-12-01)
To compare the diagnostic value of contrast-enhanced CT (ceCT) and 2-[18-F]-fluoro-2-deoxyglucose-PET/CT in patients with metastatic colorectal cancer to the liver. Despite preoperative evaluation with ceCT, the tumor load in patients with metastatic colorectal cancer to the liver is often underestimated.
Amina Abdelmoumene et al.
European radiology, 15(9), 1881-1887 (2005-05-04)
This study compared different acquisition protocols performance to detect small liver metastases (<2 cm). Thirty consecutive patients with histologically proven hepatic metastases were explored by MDCT at the liver equilibrium phase by four successive acquisitions. We compared the following protocols
S G Spitzer et al.
Acta radiologica (Stockholm, Sweden : 1987), 43(6), 617-622 (2002-12-18)
To investigate the influence of two non-ionic radiographic contrast media with different osmolality on thrombocytic function and the plasmatic coagulation system. The study was carried out as a randomised, prospective, comparative study with two contrast media in a heart catheter
Severe Stevens-Johnson syndrome induced by contrast medium iopentol (Imagopaque).
E Laffitte et al.
The British journal of dermatology, 150(2), 376-378 (2004-03-05)
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique